The efficacy of recombinant feline interferon-omega in treating symptomatic cats infected with feline immunodeficiency virus
PICO Question In symptomatic cats with feline immunodeficiency virus (FIV), does high-dose subcutaneous recombinant feline interferon-omega (rFeIFN-ω) administration lead to reduced clinical signs compared to cats who were not administered rFeIFN-ω? Clinical bottom line Category of research Treatm...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
RCVS Knowledge
2023-09-01
|
| Series: | Veterinary Evidence |
| Subjects: | |
| Online Access: | https://veterinaryevidence.org/index.php/ve/article/view/666 |
| _version_ | 1827383705159598080 |
|---|---|
| author | Rachel Garrett |
| author_facet | Rachel Garrett |
| author_sort | Rachel Garrett |
| collection | DOAJ |
| description | PICO Question In symptomatic cats with feline immunodeficiency virus (FIV), does high-dose subcutaneous recombinant feline interferon-omega (rFeIFN-ω) administration lead to reduced clinical signs compared to cats who were not administered rFeIFN-ω? Clinical bottom line Category of research Treatment. Number and type of study designs reviewed Three studies were critically reviewed, including one randomised controlled trial, one non-randomised controlled trial, and one uncontrolled clinical trial. Strength of evidence Weak. Outcomes reported Each of the studies reported that rFeIFN-ω administration significantly reduced clinical signs in FIV infected cats. However, all three papers have limitations in their study design and statistical analysis which lower the strength of the evidence they provide. Conclusion There is only weak evidence demonstrating that rFeIFN-ω administration leads to reduced clinical signs in FIV positive cats. Currently, there is a lack of well-designed, double-blinded, randomised, placebo-controlled clinical trials which have an adequate sample size and specifically focus on FIV positive cats. As a result, more robust evidence is needed to prove the definitive therapeutic benefit of rFeIFN-ω in symptomatic FIV patients. Treatment with rFeIFN-ω may still be considered by clinicians for cats with clinical signs potentially associated with retroviral infection, such as oral lesions and stomatitis, particularly if they are not responding well to supportive therapy alone. How to apply this evidence in practice The application of evidence into practice should take into account multiple factors, not limited to: individual clinical expertise, patient’s circumstances and owners’ values, country, location or clinic where you work, the individual case in front of you, the availability of therapies and resources. Knowledge Summaries are a resource to help reinforce or inform decision making. They do not override the responsibility or judgement of the practitioner to do what is best for the animal in their care. |
| first_indexed | 2024-03-08T14:45:03Z |
| format | Article |
| id | doaj.art-7904755b48e94bd9b49a1f3be39969d0 |
| institution | Directory Open Access Journal |
| issn | 2396-9776 |
| language | English |
| last_indexed | 2024-03-08T14:45:03Z |
| publishDate | 2023-09-01 |
| publisher | RCVS Knowledge |
| record_format | Article |
| series | Veterinary Evidence |
| spelling | doaj.art-7904755b48e94bd9b49a1f3be39969d02024-01-11T11:50:09ZengRCVS KnowledgeVeterinary Evidence2396-97762023-09-018310.18849/ve.v8i3.666518The efficacy of recombinant feline interferon-omega in treating symptomatic cats infected with feline immunodeficiency virusRachel Garretthttps://orcid.org/0000-0002-0939-7329PICO Question In symptomatic cats with feline immunodeficiency virus (FIV), does high-dose subcutaneous recombinant feline interferon-omega (rFeIFN-ω) administration lead to reduced clinical signs compared to cats who were not administered rFeIFN-ω? Clinical bottom line Category of research Treatment. Number and type of study designs reviewed Three studies were critically reviewed, including one randomised controlled trial, one non-randomised controlled trial, and one uncontrolled clinical trial. Strength of evidence Weak. Outcomes reported Each of the studies reported that rFeIFN-ω administration significantly reduced clinical signs in FIV infected cats. However, all three papers have limitations in their study design and statistical analysis which lower the strength of the evidence they provide. Conclusion There is only weak evidence demonstrating that rFeIFN-ω administration leads to reduced clinical signs in FIV positive cats. Currently, there is a lack of well-designed, double-blinded, randomised, placebo-controlled clinical trials which have an adequate sample size and specifically focus on FIV positive cats. As a result, more robust evidence is needed to prove the definitive therapeutic benefit of rFeIFN-ω in symptomatic FIV patients. Treatment with rFeIFN-ω may still be considered by clinicians for cats with clinical signs potentially associated with retroviral infection, such as oral lesions and stomatitis, particularly if they are not responding well to supportive therapy alone. How to apply this evidence in practice The application of evidence into practice should take into account multiple factors, not limited to: individual clinical expertise, patient’s circumstances and owners’ values, country, location or clinic where you work, the individual case in front of you, the availability of therapies and resources. Knowledge Summaries are a resource to help reinforce or inform decision making. They do not override the responsibility or judgement of the practitioner to do what is best for the animal in their care.https://veterinaryevidence.org/index.php/ve/article/view/666catsfeline immunodeficiency virusretrovirusinterferon-omegavirbagen® omegatherapy |
| spellingShingle | Rachel Garrett The efficacy of recombinant feline interferon-omega in treating symptomatic cats infected with feline immunodeficiency virus Veterinary Evidence cats feline immunodeficiency virus retrovirus interferon-omega virbagen® omega therapy |
| title | The efficacy of recombinant feline interferon-omega in treating symptomatic cats infected with feline immunodeficiency virus |
| title_full | The efficacy of recombinant feline interferon-omega in treating symptomatic cats infected with feline immunodeficiency virus |
| title_fullStr | The efficacy of recombinant feline interferon-omega in treating symptomatic cats infected with feline immunodeficiency virus |
| title_full_unstemmed | The efficacy of recombinant feline interferon-omega in treating symptomatic cats infected with feline immunodeficiency virus |
| title_short | The efficacy of recombinant feline interferon-omega in treating symptomatic cats infected with feline immunodeficiency virus |
| title_sort | efficacy of recombinant feline interferon omega in treating symptomatic cats infected with feline immunodeficiency virus |
| topic | cats feline immunodeficiency virus retrovirus interferon-omega virbagen® omega therapy |
| url | https://veterinaryevidence.org/index.php/ve/article/view/666 |
| work_keys_str_mv | AT rachelgarrett theefficacyofrecombinantfelineinterferonomegaintreatingsymptomaticcatsinfectedwithfelineimmunodeficiencyvirus AT rachelgarrett efficacyofrecombinantfelineinterferonomegaintreatingsymptomaticcatsinfectedwithfelineimmunodeficiencyvirus |